Adeno-Associated Virus Gene Therapies (Agilis Biotherapeutics & Gene Therapy Research Institution) Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Joint Venture

  • Financing Rounds
  • 1

Adeno-Associated Virus Gene Therapies (Agilis Biotherapeutics & Gene Therapy Research Institution) General Information

Description

Developer of adeno-associated virus (AAV) gene therapies. The company's gene therapies will use Sf9 baculovirus and HEK293 mammalian cell systems and operate a process development with production facility located in the Tokyo area designed to meet international manufacturing standards, including cGMP, GCTP and PIC/S GMP requirements, enabling customers avail quality drug.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Japan
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • Japan

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Adeno-Associated Virus Gene Therapies (Agilis Biotherapeutics & Gene Therapy Research Institution) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Adeno-Associated Virus Gene Therapies (Agilis Biotherapeutics & Gene Therapy Research Institution)‘s full profile, request access.

Request a free trial

Adeno-Associated Virus Gene Therapies (Agilis Biotherapeutics & Gene Therapy Research Institution) Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Adeno-Associated Virus Gene Therapies (Agilis Biotherapeutics & Gene Therapy Research Institution)‘s full profile, request access.

Request a free trial

Adeno-Associated Virus Gene Therapies (Agilis Biotherapeutics & Gene Therapy Research Institution) FAQs

  • When was Adeno-Associated Virus Gene Therapies (Agilis Biotherapeutics & Gene Therapy Research Institution) founded?

    Adeno-Associated Virus Gene Therapies (Agilis Biotherapeutics & Gene Therapy Research Institution) was founded in 2017.

  • Where is Adeno-Associated Virus Gene Therapies (Agilis Biotherapeutics & Gene Therapy Research Institution) headquartered?

    Adeno-Associated Virus Gene Therapies (Agilis Biotherapeutics & Gene Therapy Research Institution) is headquartered in Japan.

  • What industry is Adeno-Associated Virus Gene Therapies (Agilis Biotherapeutics & Gene Therapy Research Institution) in?

    Adeno-Associated Virus Gene Therapies (Agilis Biotherapeutics & Gene Therapy Research Institution)’s primary industry is Drug Discovery.

  • Is Adeno-Associated Virus Gene Therapies (Agilis Biotherapeutics & Gene Therapy Research Institution) a private or public company?

    Adeno-Associated Virus Gene Therapies (Agilis Biotherapeutics & Gene Therapy Research Institution) is a Private company.

  • What is Adeno-Associated Virus Gene Therapies (Agilis Biotherapeutics & Gene Therapy Research Institution)’s current revenue?

    The current revenue for Adeno-Associated Virus Gene Therapies (Agilis Biotherapeutics & Gene Therapy Research Institution) is .

  • Who are Adeno-Associated Virus Gene Therapies (Agilis Biotherapeutics & Gene Therapy Research Institution)’s investors?

    Agilis Biotherapeutics and ONODERA GT Pharma have invested in Adeno-Associated Virus Gene Therapies (Agilis Biotherapeutics & Gene Therapy Research Institution).

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process